Evidence map›Paper›PMID 37217493›Full record

ArticleCell death & disease2023

The deleted in oral cancer (DOC1 aka CDK2AP1) tumor suppressor gene is downregulated in oral squamous cell carcinoma by multiple microRNAs.

Roberto Stabile, Mario Román Cabezas, Mathijs P Verhagen, Francesco A Tucci, Thierry P P van den Bosch, Maria J De Herdt, Berdine van der Steen, Alex L Nigg, Meng Chen, Cristina Ivan and 7 more

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 9 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 4 countries.

Roberto StabileDepartment of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Mario Román CabezasDepartment of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands.ORCID 0009-0002-1318-1552
Mathijs P VerhagenDepartment of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands.ORCID 0000-0003-3126-8379
Francesco A TucciDepartment of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands.ORCID 0000-0001-6247-5392
Thierry P P van den BoschDepartment of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Maria J De HerdtDepartment of Otorhinolaryngology and Head & Neck Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands.
Berdine van der SteenDepartment of Otorhinolaryngology and Head & Neck Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands.
Alex L NiggDepartment of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Meng ChenDepartment of Translational Molecular Pathology and Center of Department of Translational Molecular Pathology, and Center for RNA Interference and Non-Coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Cristina IvanDepartment of Translational Molecular Pathology and Center of Department of Translational Molecular Pathology, and Center for RNA Interference and Non-Coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Masayoshi ShimizuDepartment of Translational Molecular Pathology and Center of Department of Translational Molecular Pathology, and Center for RNA Interference and Non-Coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Senada KoljenovićDepartment of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Jose A HardilloDepartment of Otorhinolaryngology and Head & Neck Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands.
C Peter VerrijzerDepartment of Biochemistry, Erasmus University Medical Center, Rotterdam, The Netherlands.
Robert J Baatenburg de JongDepartment of Otorhinolaryngology and Head & Neck Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands.
George A CalinDepartment of Translational Molecular Pathology and Center of Department of Translational Molecular Pathology, and Center for RNA Interference and Non-Coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-7427-0578
Riccardo FoddeDepartment of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands. r.fodde@erasmusmc.nl.ORCID 0000-0001-9839-4324
Erasmus MC · NLThe University of Texas MD Anderson Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cyclin-dependent kinase 2-associated protein 1 (CDK2AP1; also known as deleted in oral cancer or DOC1) is a tumor suppressor gene known to play functional roles in both cell cycle regulation and in the epigenetic control of embryonic stem cell differentiation, the latter as a core subunit of the nucleosome remodeling and histone deacetylation (NuRD) complex. In the vast majority of oral squamous cell carcinomas (OSCC), expression of the CDK2AP1 protein is reduced or lost. Notwithstanding the latter (and the DOC1 acronym), mutations or deletions in its coding sequence are extremely rare. Accordingly, CDK2AP1 protein-deficient oral cancer cell lines express as much CDK2AP1 mRNA as proficient cell lines. Here, by combining in silico and in vitro approaches, and by taking advantage of patient-derived data and tumor material in the analysis of loss of CDK2AP1 expression, we identified a set of microRNAs, namely miR-21-5p, miR-23b-3p, miR-26b-5p, miR-93-5p, and miR-155-5p, which inhibit its translation in both cell lines and patient-derived OSCCs. Of note, no synergistic effects were observed of the different miRs on the CDK2AP1-3-UTR common target. We also developed a novel approach to the combined ISH/IF tissue microarray analysis to study the expression patterns of miRs and their target genes in the context of tumor architecture. Last, we show that CDK2AP1 loss, as the result of miRNA expression, correlates with overall survival, thus highlighting the clinical relevance of these processes for carcinomas of the oral cavity.

Indexed as

MicroRNAsMouth NeoplasmsSquamous Cell Carcinoma of Head and NeckTumor Suppressor ProteinsCell Line, TumorCell ProliferationCyclin-Dependent Kinase Inhibitor ProteinsGene Expression Regulation, NeoplasticGenes, Tumor SuppressorHumansCDK2AP1 protein, humanCyclin-Dependent Kinase Inhibitor ProteinsMicroRNAsTumor Suppressor Proteins

Identifiers

PMID37217493
PMCPMC10202934
OpenAlexW4377289113

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.